EMMA (Emmaus Life Sciences) Interest Expense : $-5.49 Mil (TTM As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Emmaus Life Sciences's interest expense for the three months ended in Dec. 2024 was $ -1.28 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.49 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Emmaus Life Sciences's Operating Income for the three months ended in Dec. 2024 was $ -0.56 Mil. Emmaus Life Sciences's Interest Expense for the three months ended in Dec. 2024 was $ -1.28 Mil. Emmaus Life Sciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emmaus Life Sciences Interest Expense Historical Data

The historical data trend for Emmaus Life Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Interest Expense Chart

Emmaus Life Sciences Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-5.99

-3.10

-5.01

-7.38

-5.49

Emmaus Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-2.18	-1.91	-0.97	-1.34	-1.28

Emmaus Life Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.49 Mil.

Emmaus Life Sciences (OTCPK:EMMA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Emmaus Life Sciences's Interest Expense for the three months ended in Dec. 2024 was $-1.28 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-0.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $3.06 Mil.

Emmaus Life Sciences's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Emmaus Life Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Emmaus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website

https://www.emmausmedical.com

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Executives

Seah H. Lim	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee	director, officer: Vice Chairman & COO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara	director, 10 percent owner, officer: Chairman and CEO	20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi	director	1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark	officer: SVP, Clinical Development	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich	officer: CIO & SVP	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood	director	956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii	officer: Chief Financial Officer	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato	director	3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran	officer: Chief Administrative Officer	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey	director	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki	officer: Sr. VP Finance	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501